Clear Labs

Clear Labs is a biotechnology and robotics company based in the United States, founded in 2014. The company is a provider of fully automated next-generation sequencing platforms, software, and robotics for turnkey diagnostics. Clear Labs harnesses the power of next-generation sequencing (NGS) to simplify complex diagnostics for clinical and applied markets. Their fully automated platform combines DNA sequencing, robotics, and cloud-based analytics to democratize genomics applications and deliver increased clarity. The company's solution accelerates outcomes and improves accuracy across various areas such as food-borne pathogens, infectious diseases (including SARS CoV-2), and tracking and mitigating novel pathogens. In May 2021, Clear Labs secured a noteworthy $60.00M Series C investment from a consortium of investors including Wing VC, Felicis Ventures, GV, Khosla Ventures, Menlo Ventures, Redmile Group, T. Rowe Price, Pfeffer Capital, Counterpoint Global, and Dafgårds. Clear Labs' innovative approach utilizing NGS, robotics, and cloud-based analytics demonstrates potential for significant disruption and advancement in the biotechnology and diagnostics space. Their recent strategic investment is a testament to the confidence of prominent venture capital firms in the company's technology and potential for growth and impact within the industry.